THC Pill Cuts PTSD Nightmares in Trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Dronabinol (purified THC) was more than twice as likely as placebo to produce complete cessation of nightmares in 171 PTSD patients over a 10-week randomized trial published in Nature Medicine.
- Stefan Röpke at Charité–Universitätsmedizin Berlin led the study — 87 participants took dronabinol nightly (starting at 2.5 mg, up to 15 mg) while 84 took a placebo, with nightmare severity dropping roughly 3.7 points in the drug group, 1.5 points more than placebo.
- 58% of the dronabinol group achieved at least a 50% reduction in nightmare frequency and intensity compared with 29% on placebo, and 37% experienced complete cessation versus 15% — a magnitude Röpke called the most striking finding.
- Around 4 in 5 participants correctly guessed they were receiving dronabinol rather than placebo — its psychoactive effects effectively broke the blind, meaning expectancy effects could account for some of the gap, Röpke acknowledged.
- Carrie Cuttler at Washington State University called the effect size clinically relevant but warned that THC suppresses REM sleep, so discontinuation triggers an "REM rebound" of worse nightmares — potentially driving nightly use and cannabis use disorder.
- Seven dronabinol participants experienced serious adverse events during the trial, though the researchers attributed none of them to the treatment, and Röpke stressed the drug should be prescribed and monitored by a physician, not self-administered.
Why it matters: For the roughly 4% of people globally who develop PTSD and lack access to trauma therapy, dronabinol offers the first pharmaceutical option specifically targeting nightmares — but the study's failure to blind (4 in 5 correctly identified their group) and the REM rebound risk mean it remains a physician-supervised treatment, not a substitute for trauma-focused therapy.
Ask SkimNews
